Fresenius: Jefferies raises target price
(CercleFinance.com) - Jefferies maintains its "buy" rating on Fresenius share, increasing its target price for them from E33 to E38 in the wake of EPS assumptions that have been raised by 1%-4% for 2024-26, following an investor day and Kabi's raised targets.
"We still leave upside to the "upper end" of MT guidance given uncertainties around key projects in MedTech & Biopharma)," the broker says about the German healthcare group.
"As FRE implements its key strategic processes incl. FME deconsolidation, we see significant upside potential with multiple expansion," it adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"We still leave upside to the "upper end" of MT guidance given uncertainties around key projects in MedTech & Biopharma)," the broker says about the German healthcare group.
"As FRE implements its key strategic processes incl. FME deconsolidation, we see significant upside potential with multiple expansion," it adds.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.